BDI "Ellison, Expected to Develop World's First Inhalable Lung Cancer Treatment"
[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 25th that its subsidiary Ellison plans to pursue final FDA approval for the inhalation lung cancer treatment ‘ILC,’ which is currently undergoing Phase 2 clinical trials in the United States, by applying maintenance therapy for patients who have received first-line treatment for lung cancer. ILC is effective not only for lung cancer but also for pediatric osteosarcoma, and Phase 3 clinical trials for approval as a pediatric osteosarcoma treatment are planned to begin next year.
Since the clinical course of lung cancer varies depending on the patient, the types of treatments and administration methods are also applied differently. Most lung cancer treatments currently sold in the global market are injectable or oral products, and to date, no inhalation lung cancer treatment has been approved by the US FDA.
ILC is an inhalation therapy that delivers the drug directly to the lungs, which allows for rapid onset of effects. It can achieve the desired efficacy with a small dose, resulting in fewer side effects even with long-term use. ILC is a new drug substance that combines a lipid layer with ‘cisplatin,’ widely used in various cancers, and has already been designated as an orphan drug in the US and Europe.
An Ellison representative stated, “ILC is a new drug candidate that can address the problems of existing lung cancer treatments, which cause serious side effects such as unnecessary toxicity, and due to the characteristics of the inhalation product, it has a high therapeutic effect. The drug’s safety has been verified through a total of four clinical trials, including Phase 2 trials for osteosarcoma.”
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
They added, “Since ILC has a high potential to become the world’s first inhalation lung cancer treatment, we are also considering conducting Phase 3 clinical trials in collaboration with global pharmaceutical companies.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
